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Epilepsy is a common neurologic disorder affecting 
about 1% of the population.1 The prevalence of active 
epilepsy in Kerman is 7.87/1000.2 In 23 countries of 
Asia the rate of epilepsy is the same as USA and 
Europe. Pharmacotherapy with antiepileptic drugs is 
the major treatment modality for epilepsy. This 
treatment could be a result of decreased excitation 
concurrent with increased inhibition.3 The 
management of epilepsy differs from the treatment of 
other chronic diseases; a single breakthrough event 
has a major negative effect on the quality of life. 
The past decade has brought many advances to the 
treatment of epilepsy, including many new 
pharmacological agents. Lamotrigine is one of the 
new antiepileptic drugs, which has been used for 
more than two decades. Lamotrigine is effective in 
partial-onset and secondarily generalized tonic-clonic 
seizures, primary generalized seizures (i.e., absence 
seizures, and primary generalized tonic-clonic 
seizures), atypical absence seizures, tonic/atonic 
seizures, and Lennox-Gastaut syndrome. It is 
sometimes effective for myoclonic seizures, but it can 
worsen myoclonic seizures in some patients with 
juvenile myoclonic epilepsy or myoclonic epilepsy of 
infants.  
One of the main advantages of lamotrigine is that it 
causes less cognitive impairment or overt sedation 
compared with other treatments.4 Its anti-aging effect 
on an animal model in a study has found that 
lamotrigine decreases mortality and increases 
lifespan.  
Lamotrigine has many side effects; the most 
important of which is allergic reactions. Introducing 
lamotrigine gradually is one of the keys to reducing the 
frequency and severity of allergic reactions. Although 
the incidence of cutaneous reactions to lamotrigine is 
high, the incidence of serious eruptions such as 
erythema multiform, Stevens-Johnson syndrome, and 
toxic epidermal necrolysis is low.5 In this study we 
evaluated the effects of lamotrigine on epileptic patients.  
All epileptic patients who referred to our clinic 
were evaluated. We started with low dose  
(25-50 mg/day) lamotrigine and gradually increased 
dosage until the patients became seizure free or 
adverse events appeared. At first, we used lamotrigine 
once daily, but for patients who needed more than  
150 mg/day we used twice a day. The patients had to 
be at least 6 months seizure free to be in the control 
group. For the patients experiencing side effects of the 
drug the treatment was discontinued. The patients 
who had other diseases rather than neurological 
disorders were omitted from the study. Before starting 
the drug, we did laboratory exams including white 
blood count, blood sugar, urea, and calcium. If any 
abnormality was seen, we omitted the patients from 
the study. We performed brain MRI and 
electroencephalogram for all the patients before 
starting the drug and repeated it every 3 or 6 months. 
The patients who had normal electroencephalograms 
were also omitted. 
905 epileptic patients were treated by lamotrigine 
(male = 502, female = 403). 505 persons (male = 282, 
female = 223) completed the study (after at least 6 
months, but most of them used it for more than 2 
years). Seizure was controlled in 63.5% of patients 
with monotherapy (male = 61.6%, female = 64%); it is 
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significant that in females seizure control was more 
successful than males. The number of patients who 
needed combined therapy by sodium valproate was 
107, and the final ratio of controlling seizure was 60% 
(male = 45%, female = 77.5%). 
Lamotrigine (in the form of monotherapy or 
combination therapy) could control primary 
generalized tonic-clonic epilepsy in higher than 88%, 
secondary generalized tonic-clonic epilepsy in 71%, 
complex partial epilepsy in 72%, and juvenile 
myoclonic epilepsy in 81.5% of the patients. 
Lamotrigine (monotherapy or combined therapy) was 
effective in 96.7% of familial epileptic patients, and in 
94% of patients with known focal lesions.  
The effective dosage of lamotrigine was 100-450 
mg/day; however, in men, this dosage was higher 
than women (P > 0.05). 
 
The major adverse events that caused us to 
discontinue lamotrigine in our study included: 
cutaneous reactions in 29 cases (3%); Stevens-Johnson 
syndrome in 2 patients, severe headache in 9 cases 
(1%), exaggerated or induced myoclonic jerk in 7 cases 
(0.8%), thrombocytopenia with leucopenia in 3 cases, 
and dopa-responsive dystonia in 2 cases. We did not 
have any mortality regarding these adverse events. 
The minor adverse events were dizziness, mild 
diplopia, dry mouth, and mild headache, but we did 
not discontinue the treatment in these cases.  
Conclusion 
We recommend prescribing lamotrigine as first choice 
on secondary and primary generalized epilepsy and 
even juvenile myoclonic epilepsy, because of its 
tolerability, fewer adverse events, and low frequency 
of prescription. 
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